WS #11711
Holding: newest synthesis is 135d 13h old
AstraZeneca and Ionis' Wainua fails Phase 3 ATTR-CM trial, causing AZN stock to slump 11% and IONS to plummet; competitors ALNY and BBIO surge.
AstraZeneca/Ionis Drug Trial Failure
AstraZeneca and Ionis' Wainua fails Phase 3 ATTR-CM trial, causing AZN stock to slump 11% and IONS to plummet; competitors ALNY and BBIO surge.